Basic/Clinical Science Session

Progress and Controversies in PKD

November 08, 2019 | 02:00 PM - 04:00 PM

Location: 143, Walter E. Washington Convention Center

Session Description

Research on PKD has revealed the central role of cyclic AMP (cAMP) in the pathogenesis of kidney cysts and led to the first FDA-approved drug to slow disease progression. This session addresses recent discoveries and controversies in PKD, including the roles of primary cilia, hippo signaling, and planar cell polarity. Recent clinical trials using somatostatin analogues to alter cAMP and cyst growth are reviewed.

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Describe the multiple roles of primary cilia in the pathogenesis of PKD
  • Identify abnormalities in hippo signaling and planar cell polarity in PKD
  • Discuss clinical trials of somatostatin analogues in PKD

Learning Pathway(s)

  • Genetic Diseases of the Kidneys
  • Development and Pediatrics


  • Rachel Gallagher, PhD
  • Katharina Hopp, PhD


  • Cilia and Cystogenesis
    02:00 PM - 02:30 PM
    Saikat Mukhopadhyay, MD, PhD
  • Hippo Signaling in PKD
    02:30 PM - 03:00 PM
    Duojia D.J. Pan, PhD
  • Planar Cell Polarity in Tubulogenesis and Cystogenesis
    03:00 PM - 03:30 PM
    Jeffrey D. Axelrod, MD, PhD
  • Somatostatin Analogues for Treatment of PKD
    03:30 PM - 04:00 PM
    Ron T. Gansevoort, MD, PhD, FASN